+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


CRISPR Market - Forecasts from 2018 to 2023

  • ID: 4618285
  • Report
  • August 2018
  • Region: Global
  • 98 pages
  • Knowledge Sourcing Intelligence LLP


  • Addgene
  • CRISPR Therapeutics
  • Editas Medicine
  • Egenesis, Inc.
  • GE Healthcare
  • Lonza Group
  • MORE
The global CRISPR market is a growing industry with major investments from developed countries. Global genome editing market is witnessing high growth rate after the discovery of cutting-edge tool- “CRISPR”, a shorthand for “Clustered Regularly Interspaced Short Palindromic Repeats”. CRISPR-based tools are increasingly being adopted by the enterprises globally for new developments in fields like genome editing, genetic engineering, biotechnology, pharmaceutical, and agriculture. Global CRISPR market is estimated to grow at a CAGR of 33.26% during the forecast period to reach a total market size of US$3086.697 million by 2023 from US$551.242 million in 2017.

By Products

CRISPR-based products are applicable to any system containing genome. Gene designing tools were launched by many firms in the market due to high target efficiency and wide applications. Design tools are the major product segment of the global CRISPR market, followed by CAS9 and G RNA in terms of market share. A major vendor, Thermo Fisher Scientific launched design tools based on CRISPR, to simplify its application in genome editing and gene synthesis.

By Applications

After the introduction of CRISPR-based tools for genome manipulations in Genetic Engineering, the segment is witnessing a significant growth. Applications of CRISPR-based tools in genetic engineering is expected to grow at a substantial rate over the forecast period. G-RNA databases/libraries form a major segment of the global CRISPR market. Application of CRISPR-based tools in cell line editing and gene manipulations will also grow at a moderate rate over the next five years.

By Region

Globally, North America held the significant market share of the global CRISPR market in 2017. The US-based gene editing market is witnessing a robust growth of CRISPR-based technologies. Companies from Germany, Switzerland and other European countries are showing interest in CRISPR research and development by continuously investing in the global CRISPR-based tools along with many firms acquiring patent rights in specific regions for various CRISPR-based tools.

Competitive Insights

Genome editing, biotechnology, Agricultural crops, drug discovery are receiving huge investments from prominent firms. CRISPR Industry has several major players such as Addgene, CRISPR Therapeutics, GE Healthcare Dharmacon Inc., GenScript Biotech Corporation, Integrated DNA Technologies, Inc., Intellia Therapeutics, Inc., Thermo Fisher Scientific, Inc., and Transposagen Biopharmaceuticals, Inc. among others. Vendors of these solutions are exploring possibilities of various applications of CRISPR-CAs9 tool in gene therapy have raised more than US$ 500 million. Bayer and CRISPR Therapeutics collaborated to form a major joint venture Casebia Therapeutics in 2016 to explore possibilities of curing genetic diseases using CRISPR-based tools.

Major industry players profiled as part of the report Addgene, CRISPR Therapeutics, Editas Medicine, Egenesis, Inc., and GE Healthcare among others.


The CRISPR market has been analyzed through the following segments:

By Products
Design Tools
Plasmid and Vector
Cas9 and g-RNA
Delivery System Products

By Applications
Genome Editing
Genetic Engineering
GMO and Crops
Human Stem Cells

By Geography
North America
  • USA
  • Canada
  • Mexico
South America
  • Brazil
  • Argentina
  • France
  • Germany
  • UK
  • Italy
Middle East and Africa
  • UAE
  • Israel
  • Saudi Arabia
Asia Pacific
  • China
  • India
  • Japan
  • South Korea
Note: Product cover images may vary from those shown


  • Addgene
  • CRISPR Therapeutics
  • Editas Medicine
  • Egenesis, Inc.
  • GE Healthcare
  • Lonza Group
  • MORE
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline

2.1. Research Design
2.2. Secondary Sources


4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness

5.1. Design Tools
5.2. Plasmid and Vector
5.3. Cas9 and g-RNA
5.4. Delivery System Products

6.1. Genome Editing
6.2. Genetic Engineering
6.3. GMO and Crops
6.4. Human Stem Cells
6.5. Others

7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.1.4. Others
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. France
7.3.2. Germany
7.3.3. UK
7.3.4. Italy
7.3.5. Others
7.4. Middle East and Africa
7.4.1. UAE
7.4.2. Israel
7.4.3. Saudi Arabia
7.4.4. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. India
7.5.3. Japan
7.5.4. South Korea
7.5.5. Others

8.1. Market Share Analysis
8.2. Investment Analysis
8.3. Recent Deals
8.4. Strategies of Key Players

9.1. Addgene
9.1.1. Company Overview
9.1.2. Financials
9.1.3. Products and Services
9.1.4. Recent Developments
9.2. CRISPR Therapeutics
9.2.1. Company Overview
9.2.2. Financials
9.2.3. Products and Services
9.2.4. Recent Developments
9.3. Editas Medicine
9.3.1. Company Overview
9.3.2. Financials
9.3.3. Products and Services
9.3.4. Recent Developments
9.4. Egenesis, Inc.
9.4.1. Company Overview
9.4.2. Financials
9.4.3. Products and Services
9.4.4. Recent Developments
9.5. GE Healthcare
9.5.1. Company Overview
9.5.2. Financials
9.5.3. Products and Services
9.5.4. Recent Developments
9.6. GenScript Biotech Corporation
9.6.1. Company Overview
9.6.2. Financials
9.6.3. Products and Services
9.6.4. Recent Developments
9.7. Horizon Discovery Group PLC
9.7.1. Company Overview
9.7.2. Financials
9.7.3. Products and Services
9.7.4. Recent Developments
9.8. Integrated DNA Technologies, Inc.
9.8.1. Company Overview
9.8.2. Financials
9.8.3. Products and Services
9.8.4. Recent Developments
9.9. Intellia Therapeutics, Inc.
9.9.1. Company Overview
9.9.2. Financials
9.9.3. Products and Services
9.9.4. Recent Developments
9.10. Lonza Group
9.10.1. Company Overview
9.10.2. Financials
9.10.3. Products and Services
9.10.4. Recent Developments
Note: Product cover images may vary from those shown
  • Addgene
  • CRISPR Therapeutics
  • Editas Medicine
  • Egenesis, Inc.
  • GE Healthcare
  • GenScript Biotech Corporation
  • Horizon Discovery Group PLC
  • Integrated DNA Technologies, Inc.
  • Intellia Therapeutics, Inc.
  • Lonza Group
Note: Product cover images may vary from those shown